ONO Pharmaceutical 以 24 亿美元现金收购 Deciphera Pharmaceuticals，以扩大肿瘤学影响力和全球专科制药目标。 ONO Pharmaceutical acquires Deciphera Pharmaceuticals for $2.4bn in cash to expand oncology presence and global specialty pharma goals.
ONO Pharmaceutical 以 24 亿美元现金收购 Deciphera Pharmaceuticals，并将其与一家子公司合并，以增强其在肿瘤学领域的影响力和全球专科制药目标。 ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4bn in cash, merging them with a subsidiary to enhance its oncology presence and global specialty pharma goals. 该交易为 ONO 增添了 Deciphera 的激酶药物研究、美国/欧盟商业平台和全球临床开发能力。 The deal adds Deciphera's kinase drug research, US/EU commercial platforms, and global clinical development capabilities to ONO. 摩根大通、Goodwin Procter、美国银行证券和 Greenberg Traurig 分别担任各公司的顾问。 JPMorgan, Goodwin Procter, BofA Securities, and Greenberg Traurig serve as advisors for the respective companies.